Localization of the virus neutralizing and hemagglutinin epitopes of E1 glycoprotein of rubella virus

Chaye, Helena; Chong, Pele; Tripet, Brian; Brush, Brad; Gillam, Shirley

doi:10.1016/0042-6822(92)90572-7

Cited by 52 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the deduced amino acid sequences of the antigenic regions within E1-195-296 identified by Terry et aI. (1988), Chaye et al (1992) and Mitchell et a]. (1992) were identical in 21 of the 22 isolates studied; the only rubella virus which exhibited an amino acid substitution within one of these regions was isolated from an immunodeficient subject.…”

Section: Discussionmentioning

confidence: 90%

“…In this report, we have determined the nucleotide sequence of a region of the rubella virus genome which encodes the antigenic determinants identified on the E1 glycoprotein by Terry et al (1988), Mitchell et al (1992) and Chaye et al (1992) from a panel of 22 rubella viruses from USA, Europe and Asia isolated between 1963-1995. The panel included viruses from geographical regions not previously studied, two viruses from cases of rubella reinfection in pregnancy and one isolated from synovial fluid.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nucleotide sequence analysis of a major antigenic domain of the E1 glycoprotein of 22 rubella virus isolates

Bosma

Best

Corbett

et al. 1996

Journal of General Virology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Nucleotide sequence analysis of a major antigenic domain of the E1 glycoprotein of 22 rubella virus isolates

Bosma

Best

Corbett

et al. 1996

Journal of General Virology

View full text Add to dashboard Cite

“…Finally, sequences 701E, 719E, and 888E had particular nucleotide variations, but only sequence 701E showed the G253C amino acid alteration. This amino acid is also located in an immunoreactive region (11,14,25,33). In summary, 18 (85.7%) of the 21 specific mutations occurred at codon position 3 and remained silent.…”

Section: Resultsmentioning

confidence: 99%

“…Cluster 3 (sequences 825E, 837E, and 896E) had one additional variable nucleotide at position 328, which remained silent, and sequence 837E had one additional variable nucleotide at position 704 which affected the first base of the codon, causing a change in amino acid T394S. This amino acid maps within an immunoreactive region (11,14,25,33). Cluster 4 (577A and 581E) contained one additional variable nucleotide at position 247, which remained silent.…”

Section: Resultsmentioning

confidence: 99%

Phylogenetic Analysis of Rubella Virus Strains from an Outbreak in Madrid, Spain, from 2004 to 2005

et al. 2009

View full text Add to dashboard Cite

Rubella virus (RUBV) usually causes a mild exanthematous disease that is frequently accompanied by adenopathy and occasionally by arthralgia. Complications of this infection are rare and include encephalopathy and thrombocytopenia. However, the most severe consequence of this virus is its teratogenicity. It can cause congenital rubella syndrome (CRS) when it occurs in pregnant women, particularly during the first trimester of pregnancy (10).The direct detection of RUBV RNA in clinical specimens, in addition to the detection of RUBV-specific immunoglobulin M, is a critical factor in the early laboratory diagnosis of recent or congenital infection (18,27). Currently, the European region of the World Health Organization (WHO) aims to eliminate not only measles but also rubella and to reduce the incidence of CRS to less than one case per 100,000 live births by 2010 (38, 39). For this purpose, epidemiological surveillance based on the laboratory diagnosis of each suspected case and the characterization of the genotype of the circulating strains are included in the WHO's recommendations. In the most recent WHO update, the standard nomenclature for the classification and designation of wild-type RUBV strains recognizes nine definitive and four provisional genotypes (40), expanding the nomenclature established in 2005 (37), which was based on 739 nucleotides (nt) (nt 8731 to 9469) from the E1 gene sequence. This sequence encodes amino acids (aa) 159 to 404 (of the 481 aa) of the E1 glycoprotein. Although our knowledge of the geographic distribution of RUBV genotypes has grown substantially since 2003, the genotypes present in many countries and regions remain unknown (9), even though rubella is still recognized as a globally important disease in a general public health context (41). RUBV is considered monotypic with cross-neutralization among different genotypes.In Spain, monovalent RUBV vaccine was introduced in the late 1970s, when it was administered in schools to 11-year-old girls (1). In 1981, one dose of the measles-mumps-rubella combined vaccine was introduced in the regular immunization schedule at the age of 15 months for all children. In 1996, a second dose at 11 years of age was introduced (5). In 1999, this second dose was given to 4-year-old children (3). Currently, the seroprevalence of RUBV in the community of Madrid exceeds 95% in all age groups and reaches 98.6% among women of childbearing age (16 to 45 years) (4). Nevertheless, the pattern is very different in other regions around the world and RUBV infection remains endemic in many areas, such as Latin America (15). The rubella vaccine was only introduced in Latin American countries in the late 1990s, so that many adult immigrants to Spain are not immunized. These circumstances led to a small outbreak in Madrid in 2003 (31) and a larger one in 2004 and 2005 (2, 27) among Latin American immigrants. The main aim of this study was to characterize the RUBV strain involved in the latter outbreak, which represents the first data concerning RUBV genotypes i...

show abstract

“…Immunoprecipitation or immunoblot techniques have shown that most of the anti-RV immunoglobulin response seems to be induced by the E1 glycoprotein. Although both E1 and E2 provide lifelong immunity, the hemagglutination activity and viral neutralization activity have been attributed to the E1 protein at amino acid positions 208 to 239 (7,8), 213 to 239 (9), and 214 to 240 (10). Three additional neutralizing and hemagglutination epitopes have been identified within the E1 glycoprotein between residues 245 and 285 (11).…”

mentioning

confidence: 99%

Chimeric Derivatives of Hepatitis B Virus Core Particles Carrying Major Epitopes of the Rubella Virus E1 Glycoprotein

Skrastiņa

Petrovskis

Petraityte³

et al. 2013

Clin Vaccine Immunol

View full text Add to dashboard Cite

bThree variants of the major rubella virus (RV) E1 protein virus-neutralizing epitope from position 214 to 285 were exposed on the hepatitis B virus (HBV) C-terminally truncated core (HBc⌬) in a virus-like particle (VLP) vector and were produced in Escherichia coli. All three chimeras demonstrated VLPs in bacterial cell lysates, but only HBc⌬-E1(245-285) demonstrated the correct VLP structure after purification. The other chimeras, HBc⌬-E1(214-285) and HBc⌬-E1(214-240), appeared after purification as non-VLP aggregates of 100 to 900 nm in diameter according to dynamic light scattering data. All three variants possessed the intrinsic antigenic activity of RV E1, since they were recognized by natural human anti-RV E1 antibodies and induced an anti-RV E1 response in mice. HBc⌬-E1(214-240) and HBc⌬-E1(245-285) can be regarded as prototypes for a putative RV vaccine because they were able to induce antibodies recognizing natural RV E1 protein in RV diagnostic kits. R ubella virus (RV) is an enveloped, positive single-stranded RNA virus and a member of the genus Rubivirus, which belongs to the Togaviridae family. Rubella is normally a mild, selflimited disease but may cause fetal damage if it is acquired during the first trimester of pregnancy. In this case, congenital rubella syndrome could be generated in infants after birth (for a review, see reference 1). One of the most widely used RV vaccines, Meruvax, is a live attenuated vaccine that was propagated using the human cell line WI-38, which was derived from embryonic lung tissue in 1961 (2, 3), and is used as a component of the mixed measles, mumps, and rubella (MMR) vaccine (for a review, see reference 4). Because of the drawbacks of human cell line-derived vaccines, there is an urgent need for the construction of recombinant RV vaccine candidates.RV consists of three structural proteins: a capsid protein and two membrane-spanning glycoproteins, E1 and E2, localized in the virus envelope (5). E1 is the dominant surface molecule of the virus particle; it represents the main target for the detection and subsequent elimination of RV by the host's immune system (6, 7). Immunoprecipitation or immunoblot techniques have shown that most of the anti-RV immunoglobulin response seems to be induced by the E1 glycoprotein. Although both E1 and E2 provide lifelong immunity, the hemagglutination activity and viral neutralization activity have been attributed to the E1 protein at amino acid positions 208 to 239 (7, 8), 213 to 239 (9), and 214 to 240 (10). Three additional neutralizing and hemagglutination epitopes have been identified within the E1 glycoprotein between residues 245 and 285 (11). Therefore, these E1 protein epitopes may have potential not only in diagnostics but also in the development of vaccines against RV infection (12).The hepatitis B virus (HBV) core (HBc) protein was first reported as a promising virus-like particle (VLP) carrier in 1986 (13), and this was published in 1987 (14, 15). In many ways, HBc maintains a unique position among other VLP carriers be...

show abstract

Localization of the virus neutralizing and hemagglutinin epitopes of E1 glycoprotein of rubella virus

Cited by 52 publications

References 35 publications

Nucleotide sequence analysis of a major antigenic domain of the E1 glycoprotein of 22 rubella virus isolates

Nucleotide sequence analysis of a major antigenic domain of the E1 glycoprotein of 22 rubella virus isolates

Phylogenetic Analysis of Rubella Virus Strains from an Outbreak in Madrid, Spain, from 2004 to 2005

Chimeric Derivatives of Hepatitis B Virus Core Particles Carrying Major Epitopes of the Rubella Virus E1 Glycoprotein

Contact Info

Product

Resources

About